# TROPION-Urothelial03 (NCT07129993)

> Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

No report yet. It can be ordered.

- Drugs tested: datopotamab deruxtecan
- Indication: advanced urothelial carcinoma after enfortumab vedotin plus pembrolizumab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07129993
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Urothelial Cancer; Bladder Cancer
- Interventions: Dato-DXd; Carboplatin; Cisplatin; Gemcitabine
- Enrollment: 630
- Primary outcome: Overall Response Rate - Part A (Phase 2)
- Primary outcome: Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3)
- Primary outcome: Overall Survival - Part B (Phase 3)

## Indexed commentary on TROPION-Urothelial03 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=tropion-urothelial03-nct07129993